Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Molecular therapy for renal diseases

M S Lipkowitz1, M E Klotman, L A Bruggeman

  • 1Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA.

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|October 1, 1996
PubMed
Summary

Molecular therapy using nucleic acids offers promise for kidney disease treatment. Overcoming delivery and targeting challenges is crucial for successful organ-specific applications and future clinical translation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cellular events of acute, resolving or progressive COVID-19 in SARS-CoV-2 infected non-human primates.

Nature communications·2020
Same author

The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial.

Diabetes, obesity & metabolism·2014
Same author

Serum potassium predicts time to blood pressure response among African Americans with hypertensive nephrosclerosis.

Journal of human hypertension·2012
Same author

Conditionally replicating lentiviral-hybrid episomal vectors for suicide gene therapy.

Antiviral research·2008
Same author

HIV infection changes glomerular podocyte cytoskeletal composition and results in distinct cellular mechanical properties.

American journal of physiology. Renal physiology·2006
Same author

HIV and complement: hijacking an immune defense.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2006

Area of Science:

  • Nephrology and Molecular Therapeutics
  • Gene Therapy and Nucleic Acid Delivery
  • Renal Disease Pathophysiology

Background:

  • Molecular therapy via nucleic acids (oligonucleotides, genetic constructs) shows potential for treating renal diseases.
  • Significant hurdles exist for organ-specific kidney molecular therapy, including selective targeting, vector development, and defining therapeutic targets.
  • Clarifying the genetic and pathophysiologic basis of kidney diseases will reveal specific targets like polycystin, HIV-1, alpha-galactosidase A, insulin, and collagen IV chains.

Purpose of the Study:

  • To review the potential and challenges of molecular therapy for renal diseases.
  • To identify key barriers to successful kidney-specific molecular therapy.
  • To discuss potential molecular targets and therapeutic strategies for progressive renal diseases.

Related Experiment Videos

Main Methods:

  • Review of current literature on molecular therapy approaches for renal diseases.
  • Discussion of challenges in gene delivery, vector development, and target identification for kidney applications.
  • Exploration of potential therapeutic targets and strategies, including antisense oligodeoxynucleotides and ribozymes.

Main Results:

  • The kidney's accessibility via multiple routes (intrarenal artery, uroexcretory pathways, ex vivo) presents an advantage for molecular therapy delivery.
  • Development of tropic vectors and tissue-specific promoters is necessary for restricted kidney expression.
  • Further understanding of transport, specificity, and in vivo mechanisms of action for nucleic acid delivery is required.

Conclusions:

  • Successful kidney-specific molecular therapy requires addressing challenges in targeting, vector development, and long-term regulated expression.
  • Appropriate animal models are essential for demonstrating in vivo efficacy.
  • A cautious, thorough approach is needed to avoid premature clinical application and maintain enthusiasm for this promising therapeutic field.